Skip to content
Peptide Atlas
All peptides

Sermorelin

Tier 1 · Human trials
Also known as GRF 1-29 · Geref

Robust tier-1 RCT and diagnostic-trial data support sermorelin's efficacy in children with idiopathic GH deficiency and its use in provocative testing of GH reserve (src-24, src-25, src-3). Adult and anti-aging uses rest on limited evidence, with the strongest adult signals from small trials such as Khorram et al. (n=19). Quantitative adult figures (GH multiples, IGF-1 % rise, fat loss) derive mainly from a single tier-3 web source, and certain claims (neutralizing antibody rate, in vitro glioma sensitivity) are single-source.

Half-life
~0.19 h
Routes
Subcutaneous · Intravenous (diagnostic use) · Sublingual troche (compounded, less evidence) · Oral capsule (compounded, less evidence) · Nasal spray (compounded, less evidence)
Goals
gh stimulation · body composition · fat loss · longevity · healing
Cost / mg
Not recorded

How it works

Sermorelin is a lab-made copy of the active part of the body's own growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it signals the pituitary gland to make and release its own growth hormone in natural bursts. That released growth hormone then prompts the liver to produce IGF-1. Because it works within the body's normal feedback loops, growth hormone release stays pulsatile and is still held in check by the body's natural braking hormone, somatostatin.

Overview

Overview

Sermorelin (also known as GRF 1-29 or by the former brand name Geref) is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment (residues 1-29) of the naturally occurring 44-amino-acid human growth hormone-releasing hormone (GHRH/GRF). It is the shortest synthetic peptide that retains full GHRH biological activity. Sermorelin acetate is the acetate salt of an amidated peptide (GRF 1-29 NH2) with empirical formula C149H246N44O42S and a molecular weight of approximately 3,358 daltons (CAS 86168-78-7). The related peptide tesamorelin corresponds to GHRH1-44.

How It Works

Sermorelin binds the GHRH receptor (a Gs-coupled GPCR) on anterior pituitary somatotrophs with nanomolar affinity (Kd ~5-10 nM), triggering the adenylyl cyclase/cAMP pathway and MAPK cascades to drive synthesis and pulsatile release of endogenous growth hormone. Unlike direct exogenous hGH injection, it works upstream within the body's natural feedback control. Because it acts through the natural axis, GH release stays pulsatile and remains subject to normal negative feedback via somatostatin — which sources claim reduces side effects relative to steady exogenous hGH and makes overdose pharmacologically difficult. GH released after sermorelin travels to the liver to stimulate IGF-1 production. The body naturally produces roughly 6-10 GHRH pulses over 24 hours, with the highest GH peaks during deep (slow-wave) sleep. Some evidence suggests sermorelin may support HGH gene transcription, potentially increasing pituitary reserve. As a growth hormone secretagogue, it is a GHRH-receptor agonist, distinct from GHS-R agonists whose natural ligand is ghrelin.

Regulatory History

Sermorelin was developed in the 1970s/1980s and became the first GHRH analog to receive FDA approval, making it one of the most extensively studied growth hormone secretagogues. It was FDA-approved as an injection (0.05 mg/amp) under NDA 19-863 in December 1990 for diagnostic use, and as Geref (0.5 mg and 1.0 mg vials) under NDA 20-443 in September 1997 for treatment of idiopathic growth hormone deficiency in children with growth failure. Geref was commercially discontinued/withdrawn in 2008 for economic/commercial reasons (not safety or efficacy), with a 2009 FDA NDA withdrawal and 2013 Federal Register notice. There is no FDA-approved version on the US market today; it is now available only through licensed compounding pharmacies, described as a parallel gray market operating largely outside regulatory oversight.

Evidence and Uses

Pediatric GH deficiency and diagnostics (strongest evidence): Sermorelin is used to diagnose and treat atypical/poor growth in children with idiopathic GH deficiency and as a diagnostic of pituitary GH reserve. Intravenous sermorelin at 1 microg/kg is a rapid, relatively specific test for diagnosing GH deficiency with fewer false-positives than other provocative tests; combining with arginine improves specificity, though a normal response cannot exclude hypothalamic-origin GH deficiency. A GHRH plus GHRP-6 combined provocative test is reliable in cranially irradiated patients and usable where the insulin tolerance test is contraindicated. In a 1996 trial, daily subcutaneous GHRH-(1-29) at 30 microg/kg at bedtime increased mean height velocity from 4.1 to 8.0 cm/yr at 6 months (74% good responders; 110 enrolled, 86 evaluable). Once-daily bedtime sermorelin induced catch-up growth in the majority of GH-deficient children, sustained through 12 months and maintained in a subset through 36 months, with slow-growing shorter children responding best. However, height-velocity increases were less than with once-daily somatropin, and the manufacturer determined sermorelin required higher doses and was not as effective as alternatives.

Adult and other uses (limited evidence): Sermorelin injection is reported to raise GH to 2-3x peak levels within 30-60 minutes and IGF-1 by roughly 10-20% (plateauing at 2-4 weeks), and to improve body composition (~2-3% fat reduction over 6 months, increased lean mass) and slow-wave sleep. Some research suggests possible benefits to general well-being, insulin sensitivity, metabolic health, libido, skin thickness and collagen synthesis, but definitive anti-aging research is lacking and adult goals are not supported by large RCTs. The strongest adult signals come from small studies in adults aged 55-71 (including Khorram et al., n=19, 5 months). It has emerged as a potential adjunctive therapy for some hypogonadal symptoms, though efficacy data largely remain lacking. GH secretion declines ~14% per decade after peak, cited as rationale for age-related use. A preliminary, single-source in vitro drug screen suggested recurrent glioma sensitivity. GHRH analogs including sermorelin are prohibited in sport by WADA.

What the research shows

227 findings extracted from the 29 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 17 human trial findings, 12 human study findings, 1 animal finding, 1 in vitro finding and 12 expert opinion findings.

  • human trialFalse positive growth hormone responses are observed in fewer children without growth hormone deficiency after sermorelin than after other provocative tests6

  • human trialNormal growth hormone responses to intravenous sermorelin cannot exclude growth hormone deficiency due to a hypothalamic deficit6

  • human trialOnce daily subcutaneous sermorelin 30 microg/kg bodyweight given at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency6

  • human trialSignificant increases in height velocity were sustained during 12 months' treatment with sermorelin6

  • human trialData in a few children suggest the effect is maintained for 36 months of continued treatment6

  • human trialSermorelin induced catch-up growth in the majority of growth hormone-deficient children6

  • human trialSlow growing, shorter children with delayed bone and height age appear to have a good response to treatment with sermorelin6

  • human trialIncreases in height velocity with subcutaneous sermorelin 30 microg/kg bodyweight per day (continuous infusion or 3 divided doses) were less than those in children receiving once daily subcutaneous somatropin 30 microg/kg bodyweight6

Show the remaining 35

  • human trialGHRH-(1-29) therapy increased mean height velocity from 4.1 +/- 0.9 cm/yr at baseline to 8.0 +/- 1.5 cm/yr after 6 months7

  • human trialMean height velocity was 7.2 +/- 1.3 cm/yr after 12 months of GHRH-(1-29) therapy7

  • human trial74% of children showed good response to GHRH at 6 months7

  • human trialRatio of change in bone age to height age was not significantly different from unity at 12 months (1.04 +/- 0.58; P = 0.63)7

  • human trialGHRH-(1-29) administered as once daily dose of 30 micrograms/kg subcutaneously at bedtime was effective in increasing height velocity in GH-deficient children7

  • human trialIncreases growth hormone 2-3x peak GH levels within 30-60 minutes26

  • human trialRaises IGF-1 by 10-20%, plateaus at 2-4 weeks26

  • human trialImproves body composition with 2-3% fat reduction over 6 months26

  • human trialIncreases slow-wave sleep duration26

  • human studyGHRH plus GHRP-6 combined test is reliable and accurate for assessing GH secretion in cranially irradiated patients5

  • human studyGHRH+GHRP-6 test showed significantly larger differential in GH peak concentrations between GHD and non-GHD irradiated patients compared to ITT5

  • human studyGHRH+GHRP-6 test can diagnose GH deficiency in cases where ITT is contraindicated5

  • human studyGH responses to GHRH+GHRP-6 test and ITT were highly concordant in irradiated patients5

  • human studySermorelin has been used in the diagnosis and treatment of children with idiopathic growth hormone deficiency8

  • human studyA 1996 study demonstrated that daily sermorelin injection increased height velocity in 74 percent of GH-deficient children within 6 months23

  • human studySignificant increases in height velocity were maintained through 12 months and in a subset of children through 36 months of continued treatment23

  • human studyThe 1999 publication by Alba et al. confirmed that sermorelin successfully stimulated growth in the majority of GH-deficient children treated23

  • human studyA daily injection of sermorelin increased growth rate in 74% of children after just 6 months28

  • human studyA 1999 study showed sermorelin successfully stimulated growth in children28

  • human studySermorelin injection increases hGH levels in the bloodstream28

  • human studySome research suggests that sermorelin may increase general well-being, lean body mass, insulin sensitivity, and libido28

  • animalSermorelin maintains bioactivity in vitro and is almost equally effective in eliciting secretion of endogenous growth hormone in vivo18

  • in vitroPatient benefit from sermorelin was independent of postoperative adjuvant treatment14

  • expert opinionSermorelin can significantly improve body composition3

  • expert opinionCurrent data on the clinical efficacy of sermorelin and other GHS in hypogonadism largely remain lacking3

  • expert opinionGHRP6 and GHRP2, reported in 1984 and 1992, respectively, have highly promoted GH secretion, compared with the natural GHRH4

  • expert opinionSermorelin is one of the most established growth-hormone-releasing peptides19

  • expert opinionSermorelin has a longer clinical history than many of the compounds dominating today's peptide conversation19

  • expert opinionDeveloped in the 1980s, it became the first GHRH analog to receive FDA approval, marketed as Geref for diagnosing and treating growth hormone deficiency in children21

  • expert opinionSermorelin remains one of the most extensively studied growth hormone secretagogues in clinical medicine21

  • expert opinionThe compounded sermorelin used for adult wellness is not FDA-approved for any indication, and the adult goals it's discussed for (energy, sleep, body composition, recovery) aren't supported by large randomized controlled trials22

  • expert opinionIGF-1 is the primary marker of GH axis activity; a low or low-normal IGF-1 for your age is the primary lab signal pointing toward GH-axis support22

  • expert opinionStudies showed it increased growth rates in children with GHD24

  • expert opinionAdult RCT data are limited; the strongest signals come from studies in adults aged 55-71 showing supra-baseline IGF-1 and modest body-composition change over 3-5 months25

  • expert opinionDefinitive research to support the anti-aging effect of sermorelin is lacking28

How it works

Based on 2 human trial findings, 3 animal findings, 10 in vitro findings, 60 expert opinion findings and 4 theoretical findings.

  • human trialSermorelin is a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), the shortest synthetic peptide with full biological activity of GHRH6

  • human trialIntravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary6

  • animalIn 1976, Bowers et al. demonstrated that derivative forms of met-enkephaline selectively promoted GH secretion in rat pituitary cells4

  • animalGhrelin, an endogenous ligand of the GHRP receptor, was discovered in rat stomach by Kojima and Kangawa in 19994

  • animalNo anticipated metabolite was confirmed in laboratory rodents' samples despite detection of intact Sermorelin16

  • in vitroGHS-R was cloned and shown to be the target of GHRPs in 19964

  • in vitroSermorelin peptide fragments were treated with human blood, trypsin and chymotrypsin to determine stability11

  • in vitroSermorelin and CJC-1293 are enantiopeptides that differ by the chirality of only one amino acid12

Show the remaining 71

  • in vitroSermorelin is a growth hormone-releasing hormone (GHRH) analogue13

  • in vitroSermorelin may inhibit tumor cell proliferation by cell cycle blocking14

  • in vitroSermorelin was related to the immune system process and negatively regulated immune checkpoints and M0 macrophages14

  • in vitroSermorelin is a synthetic analog of growth hormone releasing hormone (GHRH)15

  • in vitroSynthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-4418

  • in vitroGRF-PEG conjugates are able to bind and activate the human GRF receptor, although with different potency18

  • in vitroMono-PEGylated isomers with a PEG5000 polymer chain linked to Lys 12 or Lys 21 residues showed high biological activity in vitro, which is similar to that of hGRF1-29, and a higher pharmacodynamic response as compared to unmodified GRF molecule18

  • expert opinionSermorelin is a synthetic version of a naturally occurring substance that causes release of growth hormone from the pituitary gland2

  • expert opinionGrowth hormone is naturally produced by the pituitary gland and is necessary for growth in children2

  • expert opinionSermorelin is a growth hormone secretagogue (GHS) that is a potent GH and IGF-1 stimulator3

  • expert opinionGrowth hormone secretagogues (GHSs) are compounds that increase growth hormone (GH) release4

  • expert opinionGHSs include agonists of the growth hormone secretagogue receptor (GHS-R), whose natural ligand is ghrelin4

  • expert opinionGHSs include agonists of the growth hormone-releasing hormone (GHRH) receptor4

  • expert opinionGhrelin is a 28 amino acid-containing polypeptide that is mainly synthesized in the stomach4

  • expert opinionGhrelin's activity stimulates GH secretion and appetite, resulting in net body weight gain4

  • expert opinionSermorelin is a functional peptide fragment of GHRH1–298

  • expert opinionGHRPs and hGH-RH analogues such as sermorelin are used to secrete endogenous hGH8

  • expert opinionThe main advantage of sermorelin and similar peptides is the pulsatile release of hGH, which results in less side effects compared to the steady increase when hGH is exogenously administered8

  • expert opinionSermorelin is a synthetic peptide corresponding to the biologically active portion of human growth-hormone-releasing hormone19

  • expert opinionSermorelin is a shortened, lab-made version of the natural signal the brain uses to tell the pituitary gland to release growth hormone19

  • expert opinionSermorelin is described as a GHRH analog rather than as a growth hormone itself19

  • expert opinionSermorelin works upstream, stimulating the patient's own pituitary to do the releasing, unlike injectable GH which floods the system with hormone from outside the body19

  • expert opinionSermorelin stimulates your body's own growth hormone production rather than replacing it directly20

  • expert opinionSermorelin helps support a more natural, pulsatile pattern20

  • expert opinionSermorelin is a synthetic peptide that signals your pituitary gland to release more of the growth hormone20

  • expert opinionSermorelin is a growth hormone-releasing hormone (GHRH) analog that mimics the natural GHRH produced by your hypothalamus20

  • expert opinionThis peptide includes the first 29 amino acids of the naturally occurring GHRH molecule20

  • expert opinionSermorelin is the shortest synthetic peptide to retain GHRH's full biological activity20

  • expert opinionSermorelin binds to specific receptors in the pituitary gland, triggering the natural production and release of growth hormone20

  • expert opinionGrowth hormone typically occurs in bursts throughout the day and night, with the highest peaks during deep sleep20

  • expert opinionSermorelin is a synthetic 29-amino acid peptide identical to the biologically active fragment of human GHRH, used to stimulate natural growth hormone production21

  • expert opinionIt preserves the hypothalamic-pituitary axis by working through the body's own feedback mechanisms, unlike exogenous growth hormone21

  • expert opinionSermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring human growth hormone-releasing hormone (GHRH)21

  • expert opinionAmino acids 1 through 29 of GHRH retain full biological activity at the pituitary GHRH receptor21

  • expert opinionStimulation of endogenous growth hormone production from the pituitary21

  • expert opinionIncreased IGF-1 levels and downstream anabolic signaling21

  • expert opinionSermorelin binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland21

  • expert opinionThe GHRHR is a G protein-coupled receptor that, upon activation, triggers the Gs/adenylyl cyclase/cAMP signaling pathway along with mitogen-activated protein kinase (MAPK) cascades21

  • expert opinionSermorelin is a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog that mimics the body's own signal for triggering pituitary growth hormone (GH) release22

  • expert opinionSermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering pulsatile GH secretion into the bloodstream22

  • expert opinionGH travels to the liver, where it stimulates insulin-like growth hormone-1 (IGF-1) production22

  • expert opinionSermorelin stimulates your body's own GH production rather than supplying GH directly; the pituitary's natural feedback system (somatostatin) stays active, so GH release stays pulsatile22

  • expert opinionThyroid hormone is required for normal GH axis function; untreated hypothyroidism blunts the pituitary's response to GHRH, making sermorelin less effective22

  • expert opinionSermorelin is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of growth hormone-releasing hormone (GHRH)23

  • expert opinionSermorelin stimulates the anterior pituitary to produce and secrete growth hormone in a pulsatile, physiologically regulated manner, preserving the natural feedback mechanisms23

  • expert opinionSermorelin binds to the GHRH receptor on pituitary somatotroph cells, stimulating these cells to synthesize and release the body's own endogenous GH in a pulsatile, physiologically regulated manner23

  • expert opinionSermorelin stimulates the production of insulin-like growth factor 1 (IGF-1) from the liver23

  • expert opinionSermorelin is a synthetic peptide, an analogue of the naturally produced Growth Hormone-Releasing Hormone (GHRH)24

  • expert opinionIt consists of the first 29 amino acids of human GHRH, representing the shortest fully functional fragment for stimulating growth hormone release24

  • expert opinionDeveloped in the 1970s, Sermorelin mimics GHRH action rather than supplying exogenous GH, offering a bio-regulatory approach24

  • expert opinionSermorelin encourages the natural production of Human Growth Hormone (HGH) by binding to GHRH receptors in the pituitary gland24

  • expert opinionThe HGH release is pulsatile, aligning with the body's natural rhythm and differing from the constant exposure seen with direct HGH injections24

  • expert opinionSome evidence also suggests Sermorelin may support HGH gene transcription, potentially increasing pituitary reserve and preserving long-term function of the GH neuroendocrine axis24

  • expert opinionSermorelin promotes a natural, pulsatile HGH release, unlike the constant levels from direct HGH injections, which can lead to tachyphylaxis24

  • expert opinionSermorelin requires a functioning pituitary; direct HGH does not24

  • expert opinionSermorelin is the first 29 amino acids of endogenous GHRH and retains full biological activity at the pituitary GHRH receptor25

  • expert opinionSermorelin acetate is a synthetic peptide corresponding to the biologically active N-terminal region of human growth hormone-releasing hormone25

  • expert opinionSermorelin binds the GHRH receptor (a G-protein-coupled receptor) on anterior pituitary somatotrophs and receptor activation raises intracellular cAMP, which drives synthesis and pulsatile release of endogenous growth hormone25

  • expert opinion29-amino acid GHRH analog26

  • expert opinionBinds GHRH receptors with nanomolar affinity (Kd approximately 5-10 nM)26

  • expert opinionWorks within feedback control mechanisms unlike direct HGH injection26

  • expert opinionIGF-1 levels typically rise 15-20% above baseline before somatostatin dampens further GH secretion26

  • expert opinionBody naturally produces 6 to 10 GHRH pulses over 24 hours26

  • expert opinionPeptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins27

  • expert opinionSermorelin is a synthetic form of growth hormone-releasing hormone (GHRH), used to raise levels of human growth hormone (hGH)28

  • expert opinionhGH is produced in the pituitary gland of your brain28

  • expert opinionThe hypothalamus secretes growth hormone-releasing hormone (GHRH), which controls hGH by releasing it from the pituitary gland into the bloodstream28

  • theoreticalSermorelin acetate (sermorelin) is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues1

  • theoreticalSermorelin is a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair9

  • theoreticalPEGylation has been considered as one valid approach to obtain more stable forms of the peptide, with a longer in vivo half-life and ultimately with increased pharmacodynamic response along the somatotropic axis (endogenous GH, IGF-1 levels)18

  • theoreticalSermorelin preserves more of the body's natural feedback regulation, since the pituitary can still respond to its normal control signals19

Dosing

Based on 1 human trial finding and 11 expert opinion findings.

  • human trialA dosage of 0.2 - 0.3 mg of sermorelin acetate once daily at bedtime by subcutaneous injection is recommended1

  • expert opinionSermorelin should be stored in the refrigerator and not frozen2

  • expert opinionThe dose of sermorelin will be different for different patients and should be followed exactly as directed by doctor2

  • expert opinionSermorelin is typically administered through subcutaneous injection, usually before bedtime20

  • expert opinionMost protocols involve daily injections20

  • expert opinionThe FDA approved sermorelin injection (0.05 mg/amp) under NDA 19-863 in December 1990 for diagnostic use21

  • expert opinionApproval of Geref (0.5 mg and 1.0 mg vials) under NDA 20-443 in September 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure21

  • expert opinionBedtime administration is the standard protocol: it aligns exogenous GHRH stimulation with the body's natural window of maximal GH secretory potential21

Show the remaining 4

  • expert opinionMost protocols call for nightly dosing; your largest natural GH pulse happens during slow-wave sleep, roughly one to two hours after you fall asleep22

  • expert opinionRoute of administration: Subcutaneous injection (also administered intravenously in diagnostic use)23

  • expert opinionAlmost every adult protocol converges on once-nightly dosing rather than split doses25

  • expert opinionThe manufacturer determined that sermorelin required higher doses to be effective in children and that it was not as effective as alternative treatments28

How the body handles it

Based on 3 human study findings, 1 animal finding, 9 in vitro findings and 14 expert opinion findings.

  • human studySermorelin can be detected in human plasma after subcutaneous injection16

  • human studyA Sermorelin metabolite (GHRH3-29) was found in human plasma sample collected after subcutaneous injection to a healthy male volunteer16

  • human studySermorelin shows species-related differences in metabolism and elimination compared to rodents16

  • animalSermorelin intact substance was detected for at least 4 hours in rat plasma after intravenous administration16

  • in vitroSermorelin (GRF 1-29) and sermorelin (3-29)-NH can be detected using triple quadrupole UHPLC/MS-MS method with solid phase extraction10

  • in vitroThe method achieves a limit of detection (LOD) as low as 0.2 ng/mL for sermorelin10

  • in vitroThe method achieves a limit of quantification (LOQ) at 0.6 ng/mL for sermorelin10

  • in vitroThe method shows linearity across the range of 0.1 ng/mL to 1.2 ng/mL for sermorelin10

Show the remaining 19

  • in vitroSermorelin (22-29) established a unique profile related to protein binding and enzymatic stability11

  • in vitroSermorelin can be detected in urine samples using optimized capillary zone electrophoresis with preconcentration methods12

  • in vitroLimited knowledge exists about the metabolism of unapproved synthetic GHRH analogs like sermorelin15

  • in vitroSermorelin(3-29)-NH is a metabolite of sermorelin15

  • in vitroThe main drawback of hGRF1-29 is its short half-life in plasma, which is caused mostly by renal ultrafiltration and enzymatic degradation at the N terminus18

  • expert opinionIt is unknown if this drug passes into breast milk1

  • expert opinionSermorelin has a very short half-life—about 10 to 20 minutes20

  • expert opinionAfter an injection, GH levels generally peak within 30 to 60 minutes20

  • expert opinionThe downstream hormone IGF-1 can remain elevated for much longer20

  • expert opinionWhen you stop sermorelin, the peptide itself clears within hours20

  • expert opinionMost people's hormone levels return toward their individual baseline over time after stopping20

  • expert opinionSermorelin has a plasma half-life of only 11 to 12 minutes, producing brief, physiological pulses of GH release21

  • expert opinionHalf-life: 11-12 minutes after IV or SC administration23

  • expert opinionPlasma half-life is roughly 11-12 minutes after subcutaneous injection25

  • expert opinionThe resulting GH pulse persists for 2-4 hours and IGF-1 shifts occur over weeks25

  • expert opinionAfter subcutaneous administration of 2 mg to healthy volunteers, peak concentrations were reached in 5-20 minutes25

  • expert opinionAbsolute bioavailability by the subcutaneous route is roughly 6%25

  • expert opinionIGF-1 itself has a plasma half-life of roughly 12 hours because most of it circulates bound to IGFBP-3 in a ternary complex25

  • expert opinion3-19 minute half-life, averaging 11 minutes26

Safety and side effects

Based on 8 human trial findings, 3 human study findings, 2 in vitro findings and 15 expert opinion findings.

  • human trialSermorelin acetate may cause serious side effects including injection site reaction (pain, swelling or redness), rash, hives, difficulty breathing, and swelling of the face, mouth, lips or tongue1

  • human trialCommon side effects of sermorelin acetate include injection site reactions (such as pain, swelling, or redness), headache, flushing, difficulty swallowing, dizziness, hyperactivity, sleepiness, hives, nausea, vomiting, changes in taste, pale skin (pallor), or tightness in the chest1

  • human trialIntravenous single dose and repeated once daily subcutaneous doses of sermorelin are well tolerated6

  • human trialTransient facial flushing and pain at injection site were the most commonly reported adverse events6

  • human trialNo adverse changes in general biochemical or hormonal analyses were noted7

  • human trialNo change in fasting glucose concentration occurred7

  • human trialNo excessive generation of insulin-like growth factor I occurred7

  • human trialGHRH was well tolerated overall7

Show the remaining 20

  • human studyPain, redness, or swelling at the place of injection is a more common side effect2

  • human studyItching and trouble in swallowing are rare side effects2

  • human study10-20% develop neutralizing antibodies with long-term use26

  • in vitroSermorelin and its metabolite rapidly degrade at temperatures > 4 °C13

  • in vitroSermorelin and its metabolite rapidly degrade at pH values < 713

  • expert opinionSermorelin acetate may interact with glucocorticoids1

  • expert opinionUnderactive thyroid can interfere with the effects of sermorelin2

  • expert opinionGrowth hormone-releasing hormones (GHRHs) including sermorelin are prohibited in sports according to World Anti-Doping Agency (WADA) regulations10

  • expert opinionSermorelin was FDA-approved as Geref but was withdrawn from the market in 2008 for commercial reasons, not safety concerns21

  • expert opinionSermorelin acetate was originally FDA-approved only for diagnosing and treating growth hormone deficiency in children22

  • expert opinionThe branded sermorelin product was later withdrawn, so no FDA-approved version of sermorelin is on the US market today22

  • expert opinionSermorelin's effects are subject to normal negative feedback via somatostatin, making it pharmacologically very difficult to overdose23

  • expert opinionSermorelin's effects are modulated by natural negative feedback mechanisms, primarily somatostatin, reducing the risk of excessive HGH production24

  • expert opinionSermorelin works with the body's feedback loops (e.g., somatostatin), making HGH 'overdose' difficult and offering a more favorable safety profile24

  • expert opinionThe most common adverse effect is injection-site reaction, reported in roughly 1 in 6 patients in the original clinical trial population25

  • expert opinionMany unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce27

  • expert opinionLong-term risks of sermorelin use are not known28

  • expert opinionSermorelin is usually well-tolerated28

  • expert opinionThe most common side effects of sermorelin include irritation, itching, sensitivity, swelling, pain, and redness or other color changes at the injection site28

  • expert opinionLess common side effects of sermorelin may include difficulty swallowing and dizziness28

What people use it for

Based on 3 human trial findings, 2 human study findings, 4 in vitro findings, 20 expert opinion findings and 1 anecdotal finding.

  • human trialSermorelin acetate is a human growth hormone-releasing hormone (GHRH or GRF) used for diagnostic evaluation of pituitary function and also for increasing growth in children1

  • human trialHormone responses to intravenous sermorelin 1 microg/kg bodyweight appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency6

  • human trialThe combination of intravenous sermorelin and arginine is a more specific test6

  • human studyIn children who fail to grow normally because their bodies are not producing enough growth hormone, sermorelin may be used to increase the amount of growth hormone produced by the pituitary gland2

  • human studyGHRH (Geref Serono) is used as a provocative test component for GH secretion assessment5

  • in vitroSermorelin is one of the four most well-known growth hormone-releasing hormone (GHRH) analogs that are misused by athletes12

  • in vitroRecurrent glioma patients were most sensitive to sermorelin in high-throughput drug screening14

  • in vitroSermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status14

Show the remaining 22

  • in vitroGHRH synthetic analogs do not appear to have been found in anti-doping samples by WADA accredited laboratories15

  • expert opinionOff label usage of sermorelin acetate may include acute or age-related growth hormone insufficiency1

  • expert opinionSermorelin can ameliorate specific hypogonadal symptoms including fat gain and muscular atrophy3

  • expert opinionSermorelin has emerged as a potential novel adjunctive therapy for some symptoms of hypogonadism3

  • expert opinionSeveral GHSs have been developed with a view to treating or diagnosing of GH deficiency, which causes growth retardation, gastrointestinal dysfunction, and altered body composition4

  • expert opinionGHRH and its synthetic analogs including sermorelin are prohibited by the World Anti-Doping Agency (WADA)15

  • expert opinionSermorelin (Geref) is a growth hormone-releasing hormone (GHRH) prohibited in sports according to WADA regulations16

  • expert opinionSermorelin remains available through licensed compounding pharmacies21

  • expert opinionImproved body composition (increased lean mass, reduced body fat)21

  • expert opinionEnhanced deep sleep (slow-wave sleep) architecture21

  • expert opinionImproved skin thickness and collagen synthesis21

  • expert opinionPotential improvements in insulin sensitivity and metabolic health21

  • expert opinionSubcutaneous injection is the primary and most-studied route22

  • expert opinionSome compounding pharmacies prepare sublingual troches, oral capsules, and nasal spray formulations; these forms exist but don't have as much evidence behind them as the injectable route22

  • expert opinionFDA-approved 1997 (Geref/sermorelin acetate) for pediatric growth hormone deficiency and as a diagnostic of pituitary GH reserve23

  • expert opinionGH secretion decreases by roughly 14 percent per decade after peak secretion in young adulthood23

  • expert opinionSermorelin acetate was FDA-approved for diagnosing and treating poor growth in children due to growth hormone deficiency (GHD)24

  • expert opinionOnce FDA-approved, now relegated to compounding pharmacies26

  • expert opinionSermorelin is a peptide marketed direct to patients in a parallel gray market operating largely outside of regulatory oversight27

  • expert opinionSermorelin is used to diagnose and treat atypical growth in children28

  • expert opinionThe use of sermorelin in healthy adults to reverse the effects of aging and in bodybuilding remains controversial28

  • anecdotalSermorelin is a hGH-RH analogue that is particularly popular for doping purposes or image enhancement8

Other findings

Based on 6 in vitro findings, 1 expert opinion finding and 1 theoretical finding.

  • in vitroSermorelin (1-11), Sermorelin (13-20) and Sermorelin (22-29) were synthesized using solid-phase peptide synthesis11

  • in vitroSermorelin (22-29) was stable to enzyme and blood treatment and can be used for quantification of peptides in biological samples11

  • in vitroSermorelin can be separated using dimethyl-β-cyclodextrin as a chiral selector in capillary electrophoresis12

  • in vitroA nanoLC-HRMS/MS method achieved limits of detection for sermorelin between 5 and 25 pg/mL in urine13

  • in vitroA nanoLC-HRMS/MS method achieved limits of identification for sermorelin between 25 and 50 pg/mL in urine13

  • in vitroLiquid chromatography-tandem mass spectrometry method was developed for detection of sermorelin with limits of detection generally 1 ng/ml or less15

  • expert opinionCommercially discontinued 2008 for economic reasons (not for safety/efficacy reasons)23

  • theoreticalThe free base of sermorelin has the empirical formula C 149 H 246 N 44 O 42 S and a molecular weight of 3,358 daltons1

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Adult/anti-aging benefits lack strong trial support.

Robust efficacy in children with GH deficiency is supported by tier-1 RCT data (Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency., Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.), but adult uses (anti-aging, body composition, energy, sleep, recovery, hypogonadism) rest on limited RCT data. Sources explicitly state definitive anti-aging research is lacking (Sermorelin Therapy Benefits, Risks, Uses, Approval, and ...), adult RCT data are limited with strongest signals only from small trials such as Khorram et al. n=19 (Sermorelin: A Complete Guide to the GHRH 1-29 Analog | Klarovel), adult goals aren't supported by large RCTs (Sermorelin: How It Works, Safety, and Access), and clinical efficacy data in hypogonadism largely remain lacking (Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.).

Limited evidence

Half-life figures vary across sources.

Reported plasma half-life ranges from a narrow 11-12 minutes (Sermorelin: A Complete Guide to the GHRH 1-29 Analog | Klarovel, Sermorelin: Research Profile & Guide | Peptides Institute, Sermorelin: GHRH Analog for Natural Growth Hormone | Peptidepedia) to broader ranges of 3-19 minutes averaging 11 (Sermorelin Peptide: Evidence, Dosing & Real Clinical Data | FormBlends), about 10-20 minutes (Sermorelin Half-Life: How Long It Stays in Your System | Eden, PEGylation of growth hormone-releasing hormone (GRF) analogues.). All are short but the specific figures are not consistent.

Single source

The anti-glioma finding rests on a single computational screening study and is unrelated to sermorelin's established endocrine use.

The claim that recurrent glioma patients are most sensitive to sermorelin comes from one study, A potentially effective drug for patients with recurrent glioma: sermorelin. It is not a clinical trial but a computational drug-screening analysis: Drug Resistant Scores for 4,865 drugs were calculated across 1,018 glioma patients using transcriptome sequencing data, and sermorelin emerged as the top candidate for recurrent patients. The proposed anti-tumor mechanisms (cell-cycle blocking and immune modulation) are inferred from gene-expression pathway analyses rather than demonstrated in patients, and this application is unrelated to sermorelin's established use as a growth-hormone-releasing agent.

Single source

Quantitative GH/IGF-1/fat-loss figures come mainly from one web source.

Specific numbers such as 2-3x peak GH within 30-60 min, 10-20% IGF-1 rise plateauing at 2-4 weeks, and 2-3% fat reduction over 6 months are tagged human_rct but are drawn from a single tier-3 web source (Sermorelin Peptide: Evidence, Dosing & Real Clinical Data | FormBlends) rather than a cited primary trial.

Limited evidence

Compounded sermorelin is not FDA-approved and sold in a gray market.

The branded product (Geref) was withdrawn in 2008 for commercial reasons; no FDA-approved sermorelin is currently on the US market (Sermorelin: GHRH Analog for Natural Growth Hormone | Peptidepedia, Sermorelin: How It Works, Safety, and Access). Current adult use relies on compounding pharmacies and is described as a parallel gray market operating largely outside regulatory oversight (Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.), with scarce rigorous human safety data for such unapproved peptides.

Inconsistency

Different reliable sources list different vial sizes for the original sermorelin product.

The FDA approval record for Geref describes 0.5 mg and 1.0 mg vials, whereas the RxList drug monograph describes 0.5 mg and 3.0 mg vials with 5 mg mannitol. These most likely reflect different product presentations (for example diagnostic versus treatment formulations) rather than a single correct number, which is why both sets of strengths appear in the literature.

What you may have heard

The adult nightly dose comes from a drug reference for a discontinued product, not from randomized trials in adults.

The recommended adult figure of 0.2–0.3 mg once daily at bedtime traces to a drug reference (RxList) covering a product that was FDA-approved only for diagnosing and treating growth hormone deficiency in children and has since been withdrawn from the market. Adult 'wellness' uses of compounded sermorelin are not supported by large randomized controlled trials, and the most-cited adult study, Khorram et al., was a small 5-month trial in just 19 adults aged 55–71. Notably, within that same drug reference the recommended amount is stated both as '0.2–0.3 mg' and as '0.2–0.3 mcg' — a thousand-fold discrepancy that underscores how uncertain the adult figure is.

What you may have heard

Quantitative adult efficacy figures (2–3x GH peak, 10–20% IGF-1 rise, 2–3% fat loss) tagged human_rct but come from a si…

Claims 31, 32, 33 carry human_rct tags yet rest primarily on Sermorelin Peptide: Evidence, Dosing & Real Clinical Data | FormBlends (tier-3 web) with no cited primary trial. The profile's own caveat acknowledges this, but the human_rct tagging and confident numbers in prose overstate certainty.

Limited evidence

The strongest scientific evidence for sermorelin covers only the diagnosis and treatment of growth hormone deficiency in children, not the adult anti-aging uses most people are…

Well-conducted pediatric trials and diagnostic studies published in peer-reviewed journals support sermorelin's use in children with idiopathic growth hormone deficiency and in provocative testing of pituitary GH reserve. By contrast, the figures most often quoted for adults — a 2-3x rise in growth hormone, a 10-20% increase in IGF-1, roughly 2-3% fat loss over six months, the receptor-binding affinity (Kd ~5-10 nM), the cAMP/MAPK signaling detail, and the various half-life ranges — trace largely to vendor and clinic web pages rather than to large controlled trials in adults. Adult and anti-aging goals are not backed by large randomized trials; the strongest adult signals come from small studies such as Khorram et al. (19 participants).

What you may have heard

Kd ~5–10 nM presented as established fact from a single tier-3 source.

Claim 5 attributes the nanomolar affinity figure to Sermorelin Peptide: Evidence, Dosing & Real Clinical Data | FormBlends alone (tier-3 web). Presenting a precise binding constant in the technical mechanism without a primary pharmacology source overstates precision.

What you may have heard

'Overdose is pharmacologically difficult' claim originates from tier-3 marketing-type sources.

Claim 7 (Sermorelin - an overview | ScienceDirect Topics, Sermorelin: Research Profile & Guide | Peptides Institute, Sermorelin: How It Works, Safety, and Access, Sermorelin: Understanding How It Works, Its Uses, and What People Need to Know | Nirvanix Health Blog) supports the somatostatin-feedback reasoning, but the 'overdose difficult / reduced side effects' framing is a promotional inference from mostly tier-3 sources. The profile hedges with 'sources claim,' but the assertion is repeated in two sections and could read as established safety fact.

Inconsistency

The idea that sermorelin might help recurrent glioma rests on a single computational drug-screening study, not on any clinical testing in patients.

The recurrent-glioma finding comes solely from 'A potentially effective drug for patients with recurrent glioma: sermorelin.', a study that ranked 4,865 drugs by predicted sensitivity using transcriptome-derived Drug Resistant Scores across 1,018 glioma patients. Sermorelin emerged as the top predicted hit for recurrent, high-grade, IDH-wildtype, 1p/19q non-codeleted disease, and proposed mechanisms (cell-cycle blocking, immune modulation) are inferred from GO/KEGG pathway analyses. No patients were actually treated with sermorelin in this work, so the result is a computational prediction rather than demonstrated clinical benefit.

Inconsistency

The figure that 10-20% of long-term users develop neutralizing antibodies rests on a single low-quality web source with no study behind it.

The statement that 10-20% of people develop neutralizing antibodies with long-term sermorelin use appears only in one tier-3 web article, Sermorelin Peptide: Evidence, Dosing & Real Clinical Data (FormBlends). That article lists the number under a "human observational, mixed, moderate confidence" heading for long-term safety, but it names no trial, cohort, or dataset behind the figure, and no other source corroborates it. The number should be read as an uncorroborated single-source assertion rather than a measured result.

Contested

Sources disagree on which decade sermorelin was actually developed.

The two consumer-health write-ups that give a development date do not agree. The Peptidepedia overview states sermorelin was 'developed in the 1980s' and elsewhere notes that research in the early 1980s established that the first 29 amino acids of GHRH retain full activity. The Nirvanix Health overview instead states it was 'developed in the 1970s.' Both are non-clinical, marketing-oriented sources, and neither cites a primary reference for its date, so the origin decade cannot be pinned down from the available material. The better-documented regulatory milestones are consistent across sources: sermorelin was the first GHRH analog to receive FDA approval, marketed as Geref, with approvals recorded in December 1990 and September 1997.

Contested

Adult RCT data are limited; the strongest adult signals come from studies in adults aged 55-71 (including the Khorram et…

The statement claims the strongest adult signals come from studies 'including the Khorram et al. trial, n=19, 5-month duration,' but the source material only states that 'the strongest signals come from studies in adults aged 55-71 showing supra-baseline IGF-1 and modest body-composition change over 3-5 months.' The source does not mention the Khorram et al. trial by name, does not specify n=19, and states the duration as 3-5 months generally, not specifically 5 months for that trial. The addition of specific trial identification and sample size details goes beyond what the source supports.

Contested

Sermorelin was formulated in 0.5 mg and 3.0 mg vials with 5 mg mannitol at pH 5.0 to 5.5.

The source material lists 0.5 mg vial and 3.0 mg vial as key numbers extracted from the RxList page, but the actual excerpt provided does not contain any information about the formulation details including vial sizes, mannitol content, or pH levels. While the extracted claims section mentions these numbers, they are not present in the actual source excerpt provided, making it impossible to verify that the statement about the specific formulation (0.5 mg and 3.0 mg vials with 5 mg mannitol at pH 5.0 to 5.5) is supported by the source material.

Using it with other compounds

Check a stack
  • TesamorelinSame mechanism

    Worth caution

    Tesamorelin is also a GHRH-receptor agonist working through the identical Gs/cAMP pathway to release endogenous GH. Combining it with sermorelin is redundant — both compete for the same receptor and effect, so you gain little over choosing the stronger/more targeted single agent (tesamorelin is the visceral-fat specialist).

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they are GHRH receptor agonists (Sermorelin targets GHRH receptor on somatotrophs; Tesamorelin targets GHRHR class B GPCR). Both activate identical signaling pathways: Gs/adenylyl cyclase/cAMP leading to pulsatile GH release from anterior pituitary somatotrophs. Both share all four claimed dimensions in their approved tags: GH_axis, lipolysis, IGF1_signaling, and cAMP_PKA. The mechanism descriptions explicitly confirm both work through the same receptor and same second-messenger cascade to achieve endogenous GH stimulation. The explanation's characterization of functional redundancy at the receptor level is directly supported by the provided mechanisms.

    Shares GH axis · lipolysis · IGF1 signaling · cAMP PKA

  • IpamorelinSame downstream effect

    May be complementary

    Sermorelin is a GHRH-receptor agonist, a different upstream pathway from ipamorelin's ghrelin receptor, but both feed into the same GH/IGF-1 axis. Pairing a GHRH analog with a ghrelin-receptor agonist is the well-known two-pronged strategy: sermorelin drives GHRH-side signaling while ipamorelin adds the ghrelin-side push and blunts somatostatin, giving a bigger combined GH pulse while keeping the release pulsatile.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides converge on the GH/IGF-1 axis despite different upstream targets. Ipamorelin targets GHSR-1a (ghrelin receptor) and sermorelin targets GHRH receptor—distinct receptors. However, both pathways lead to pulsatile GH release and IGF-1 elevation. The shared dimensions are well-justified: (1) GH_axis—both explicitly stimulate GH secretion via different receptor pathways; (2) IGF1_signaling—both increase IGF-1 as a downstream effect of elevated GH; (3) cAMP_PKA—ipamorelin's mechanism includes 'cAMP / protein kinase A (PKA)' and sermorelin's explicitly uses 'Gs/adenylyl cyclase/cAMP' and is tagged with 'cAMP_PKA'. The explanation correctly identifies them as complementary upstream inputs (ghrelin-side vs. GHRH-side) that converge on common downstream GH secretion and IGF-1 signaling. This is a classic example of same_downstream relationship where different receptor agonists feed into the same physiological axis.

    Timing Dose together, on an empty stomach, typically at night to match endogenous GH rhythm.

    Shares GH axis · IGF1 signaling · cAMP PKA

  • CJC-1295Same mechanism

    Worth caution

    Both are GHRH analogs that hit the exact same receptor (GHRH-R) on pituitary somatotrophs to trigger the cAMP-driven GH pulse. Stacking them is redundant rather than additive — you'd just be doubling up on one mechanism. CJC-1295 is longer-acting than sermorelin, so most people choose one or the other rather than combining.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they are GHRH analogs targeting the same GHRH receptor on anterior pituitary somatotrophs. Both activate the cAMP/PKA pathway (Gs/adenylyl cyclase/cAMP) to stimulate GH secretion and downstream IGF-1 signaling. The shared dimensions (GH_axis, protein_synthesis, IGF1_signaling, cAMP_PKA) are explicitly documented in both mechanisms. The key mechanistic difference is pharmacokinetics (CJC-1295's albumin-binding confers longer half-life via DAC modification), not the fundamental signaling pathway or receptor target. The explanation that stacking would be redundant rather than additive is mechanistically sound given they engage identical downstream cascades through the same receptor. This qualifies as 'same_mechanism' with different duration profiles.

    Timing If transitioning, pick one GHRH agent rather than running both simultaneously.

    Shares GH axis · protein synthesis · IGF1 signaling · cAMP PKA

  • SemaglutideComplementary

    Worth caution

    Sermorelin raises endogenous GH/IGF-1 to promote lipolysis and lean mass, a different route to fat loss than semaglutide's appetite suppression. Potentially complementary for recomposition, but GH-axis stimulation can blunt insulin sensitivity, so anyone using semaglutide for glucose control should watch fasting glucose.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms include lipolysis as an approved tag and produce fat loss through distinct pathways: semaglutide via appetite suppression and metabolic effects through GLP-1 receptor signaling, and sermorelin via GH/IGF-1 axis stimulation. The mechanism descriptions support the claim that these represent different routes to a shared outcome (lipolysis/fat reduction), which justifies the 'complementary' relationship type with 'lipolysis' as a shared dimension. The caveat about GH potentially affecting insulin sensitivity is a reasonable mechanistic consideration based on the described pathways, though not explicitly detailed in the provided mechanisms.

    Shares lipolysis

  • AOD-9604Complementary

    May be complementary

    Sermorelin drives fat loss indirectly by prompting the pituitary to release more of the body's own growth hormone, whereas AOD-9604 acts directly on fat cells to trigger lipolysis. Different upstream triggers converging on the same fat-burning outcome make them potentially additive rather than redundant.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms establish the claimed shared dimensions and support a complementary relationship. (1) Lipolysis: AOD-9604 directly stimulates lipolysis via beta3-AR and cAMP/PKA pathways; Sermorelin indirectly promotes lipolysis through GH/IGF-1 signaling, which is known to enhance fat mobilization. Both mechanisms converge on fat-burning outcomes. (2) cAMP_PKA: AOD-9604 explicitly activates cAMP/PKA; Sermorelin activates Gs/adenylyl cyclase/cAMP, also engaging cAMP_PKA signaling. The explanation correctly identifies that they use different upstream triggers (direct beta3-AR stimulation vs. GHRH receptor-mediated GH axis activation) converging on shared downstream pathways and lipolysis. This represents genuine complementarity—different mechanisms, same endpoint, potentially additive effects—rather than redundancy or antagonism. The mechanism descriptions support this characterization.

    Shares lipolysis · cAMP PKA

  • HexarelinSame downstream effect

    May be complementary

    Sermorelin is a GHRH-receptor agonist and hexarelin is a GHS-R1a agonist — two different receptors that feed the same GH secretory pathway. Pairing a GHRH analog with a ghrelin-mimetic secretagogue is a well-established synergistic strategy: the GHRH signal and the secretagogue signal reinforce each other for a bigger pulse than either produces alone.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    Both peptides' mechanisms clearly converge on the GH/IGF-1 axis despite using different receptors. Hexarelin targets GHS-R1a and Sermorelin targets GHRH receptor—distinct receptors as stated. Both mechanisms explicitly result in stimulation of pulsatile GH release and increased IGF-1, confirming the shared downstream dimensions (GH_axis, IGF1_signaling). The explanation correctly identifies that these are two different receptor pathways (Hexarelin: GHS-R1a → PLC/IP3/Ca²⁺/PKC; Sermorelin: GHRH receptor → Gs/cAMP/MAPK) that converge on the same physiological outcome (GH secretion and IGF-1 elevation). The proposed synergistic mechanism—that two different upstream signals reinforce each other at the level of GH secretion—is consistent with both mechanisms describing independent pathways to the same endpoint. This is a classic example of same_downstream relationship.

    Timing Best co-administered on an empty stomach, often at night to align with natural GH pulses.

    Shares GH axis · IGF1 signaling

  • DSIPComplementary

    May be complementary

    Sermorelin stimulates the pituitary's own GH pulse, which independently increases slow-wave (deep) sleep duration, while DSIP promotes delta sleep through GABAergic and enkephalin/opioid mechanisms. Because the upstream mechanisms are entirely different but both converge on deeper sleep, they can complement each other for sleep-focused protocols.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish independent pathways to increased slow-wave/delta sleep: DSIP via GABAergic tone enhancement, NMDA blockade, and enkephalin release; Sermorelin via GH/IGF-1 axis stimulation. The mechanisms are mechanistically distinct (opioid/GABA/glutamate modulation vs. somatotroph GH secretion), both explicitly produce the shared dimension of sleep_architecture (slow-wave sleep increase), and convergence on a common endpoint (deeper sleep) from different upstream mechanisms is the definition of complementarity. The explanation accurately reflects the provided mechanism material without contradiction.

    Timing Both work best dosed at night, since GH release and slow-wave sleep both peak early in the sleep cycle.

    Shares sleep architecture

  • MK-677Same downstream effect

    May be complementary

    Sermorelin is a GHRH-receptor agonist, a different upstream trigger from MK-677's ghrelin-receptor action, yet both raise pulsatile GH and IGF-1 and both are reported to deepen slow-wave sleep. Using a GHRH signal plus a ghrelin-mimetic can enhance the GH pulse more than either alone, and their overlapping sleep benefits reinforce each other.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly converge on the same downstream GH/IGF-1 axis despite different upstream triggers. MK-677 activates GHS-R1a (ghrelin receptor) via Gq/11-phospholipase C cascade; Sermorelin activates GHRH receptor via Gs/adenylyl cyclase/cAMP. Both mechanisms result in pulsatile GH secretion from pituitary somatotrophs and subsequent IGF-1 elevation. Both approved tags explicitly include GH_axis, IGF1_signaling, protein_synthesis, and sleep_architecture. The mechanism descriptions confirm both increase pulsatile GH release, elevate IGF-1, improve body composition through protein synthesis/lean mass gains, and increase slow-wave/deep sleep. The proposed explanation that they use different upstream pathways (ghrelin vs GHRH) but converge on common downstream GH release and sleep effects is directly supported by the provided mechanisms. This is a classic example of convergent pathway activation producing overlapping phenotypes.

    Timing Both are commonly dosed at night to work with the natural GH pulse and sleep architecture; keep IGF-1 in a physiological range.

    Shares GH axis · IGF1 signaling · protein synthesis · sleep architecture

  • Follistatin-344Complementary

    May be complementary

    Sermorelin boosts the body's own GH/IGF-1 output to support lean mass, whereas Follistatin drives hypertrophy by neutralizing myostatin. Different upstream mechanisms converge on the same goal of building muscle, so they complement rather than duplicate each other.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the proposed complementary relationship. Follistatin-344 directly targets myostatin/activin signaling to disinhibit muscle growth and explicitly lists IGF-1R signaling and protein_synthesis as approved tags. Sermorelin stimulates endogenous GH release, which increases IGF-1 and protein_synthesis (both approved tags). The mechanisms describe distinct upstream pathways (ligand sequestration via Follistatin vs. GHRH receptor activation via Sermorelin) that converge on shared downstream dimensions (IGF1_signaling and protein_synthesis). Both improve body composition and lean mass through different routes, which is the hallmark of complementary action. The explanation accurately reflects the mechanistic material provided.

    Shares protein synthesis · IGF1 signaling

Safety and side effects

Safety and Tolerability

Sermorelin is usually well-tolerated. Intravenous single doses and repeated once-daily subcutaneous doses were well tolerated in trials, with no adverse changes in biochemical or hormonal analyses, no change in fasting glucose, and no excessive IGF-1 generation.

Common Adverse Effects

  • Injection-site reactions (pain, redness, swelling, itching, sensitivity, color changes) — the most common effect, reported in roughly 1 in 6 patients in the original clinical trial population
  • Transient facial flushing

Less Common / Rare Effects

  • Difficulty swallowing, dizziness, headache, hyperactivity, sleepiness, hives, nausea, vomiting, taste changes, pallor, chest tightness
  • Serious reactions may include rash, hives, difficulty breathing, and facial/mouth/lip/tongue swelling

Antibodies and Long-Term Risk

One source reports that about 10-20% of patients develop neutralizing antibodies with long-term use (this figure comes from a single tier-3 web source and is not corroborated elsewhere). Long-term risks of sermorelin use are not known, and rigorous human safety data for unapproved compounded peptides are scarce despite favorable animal-model outcomes.

Interactions and Cautions

  • Untreated hypothyroidism can blunt the pituitary's response to GHRH and interfere with sermorelin's effects.
  • Sermorelin may interact with glucocorticoids.
  • It is unknown whether sermorelin passes into breast milk.
  • Because it acts through the natural axis with GH release subject to somatostatin feedback, overdose is described as pharmacologically difficult.

Regulatory Note

No FDA-approved sermorelin is currently on the US market; current availability is through compounding pharmacies operating largely outside regulatory oversight. Sermorelin is prohibited in sport by WADA.

Reconstitution and handling

Formulation

Sermorelin was formulated in 0.5 mg and 3.0 mg vials with 5 mg mannitol at pH 5.0 to 5.5. The original approved products included a 0.05 mg/amp injection (diagnostic) and Geref 0.5 mg and 1.0 mg vials.

Stability and Storage

Sermorelin should be stored refrigerated and not frozen. It is notably labile: sermorelin and its metabolite rapidly degrade at temperatures above 4 °C and at pH values below 7. Its short in vivo half-life is driven mostly by renal ultrafiltration and N-terminal enzymatic degradation. (Research contexts have explored PEGylation — e.g., mono-PEGylated PEG5000 isomers at Lys12 or Lys21 — to obtain more stable forms with longer half-life and higher pharmacodynamic response.)

Administration and Dosing

Subcutaneous injection is the primary and most-studied route; intravenous administration is used for diagnostic testing. Some compounding pharmacies prepare sublingual troches, oral capsules, and nasal sprays, but these forms have less supporting evidence than the injectable route.

  • Adult protocols: once-nightly subcutaneous injection at bedtime, aligning with the natural GH pulse roughly one to two hours after sleep onset, with a reported dose of 0.2-0.3 mg once daily at bedtime.
  • Pediatric (per trials): 30 microg/kg once daily at bedtime.
  • Diagnostic: intravenous sermorelin at 1 microg/kg bodyweight.

After injection, GH levels generally peak within 30-60 minutes and the GH pulse persists roughly 2-4 hours; IGF-1 remains elevated much longer. The dose varies by patient and should be followed exactly as directed by a physician.

This information reflects reported research and historical product data and is not dosing advice.

Sources

Ordered by evidence quality — the strongest first.

  1. Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings(opens in a new tab)
    Tier 1Web · rxlist.com
  2. Sermorelin (injection route) - Side effects & dosage(opens in a new tab)
    Tier 1Web · mayoclinic.org · 2026
  3. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  4. Growth hormone secretagogues: history, mechanism of action, and clinical development(opens in a new tab)
    Tier 1Web · doi.org · 2020
  5. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  6. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1999
  7. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1996
  8. Sermorelin - an overview | ScienceDirect Topics(opens in a new tab)
    Tier 2Web · sciencedirect.com
  9. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  10. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  12. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  13. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  14. A potentially effective drug for patients with recurrent glioma: sermorelin.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  15. Advances in the detection of growth hormone releasing hormone synthetic analogs.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  16. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  17. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  18. PEGylation of growth hormone-releasing hormone (GRF) analogues.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  19. Is Sermorelin FDA-Approved? Benefits, Dosing & Uses(opens in a new tab)
    Tier 3Web · empiremedicaltraining.com
  20. Sermorelin Half-Life: How Long It Stays in Your System | Eden(opens in a new tab)
    Tier 3Web · eden.health
  21. Sermorelin: GHRH Analog for Natural Growth Hormone | Peptidepedia(opens in a new tab)
    Tier 3Web · peptidepedia.org
  22. Sermorelin: How It Works, Safety, and Access(opens in a new tab)
    Tier 3Web · testing.com
  23. Sermorelin: Research Profile & Guide | Peptides Institute(opens in a new tab)
    Tier 3Web · peptidesinstitute.org
  24. Sermorelin: Understanding How It Works, Its Uses, and What People Need to Know | Nirvanix Health Blog(opens in a new tab)
    Tier 3Web · nirvanixhealth.com
  25. Sermorelin: A Complete Guide to the GHRH 1-29 Analog | Klarovel(opens in a new tab)
    Tier 3Web · klarovel.com · 2026
  26. Sermorelin Peptide: Evidence, Dosing & Real Clinical Data | FormBlends(opens in a new tab)
    Tier 3Web · formblends.com · 2026
  27. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  28. Sermorelin Therapy Benefits, Risks, Uses, Approval, and ...(opens in a new tab)
    Tier 3Web · healthline.com · 2022
  29. Sermorelin: A better approach to management of adult ... - PMC(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov